Top plays from Phoenix Suns vs. Denver Nuggets, 01/23/2021
Top plays from Phoenix Suns vs. Denver Nuggets, 01/23/2021
Templeton Global Income Fund [NYSE: GIM] today announced a monthly distribution from net investment income of $0.0160 per share, payable on March 31, 2021, to shareholders of record on March 15, 2021 (Ex-Dividend Date: March 12, 2021).
Canadian media company Torstar Corp said it plans to launch an online casino betting brand this year, after the 2020 Ontario budget promised licenses to private operators to run businesses in the regulated online gaming market. The company's co-owner Paul Rivett said on Monday the move would help support the growth and expansion of quality community-based journalism. Torstar began publishing newspapers in 1892 and is the publisher of the Toronto Star, Canada's largest daily newspaper.
Shares of Boingo Wireless (NASDAQ: WIFI) have skyrocketed today, up by 24% as of 12:15 p.m. EST, after the company reported fourth-quarter earnings. The results were less relevant than news that Boingo Wireless is going private in an $854 million deal. The telecommunications company said it has been focused in managing its expenses in order to improve profitability, allowing it to boost adjusted EBITDA modestly despite the decrease in sales.
Slovakia is buying 2 million Sputnik V vaccines from Russia and expects half to arrive this month and next as it looks to step up vaccinations amid a surge in COVID-19 infections and deaths, the prime minister said on Monday. Speaking at a televised briefing at an airport in the east of the central European country where the first batches of the vaccine arrived, Prime Minister Igor Matovic said vaccinations could be sped up about 40% with the new supply. The country, which has the highest per-capita death rate related to COVID-19 in the past week, according to the Our World in Data website, is following Hungary in rolling out the Russian vaccine even though it lacks approval for emergency use in the European Union.
IntelePeer Appoints Chris Botting as New Chief Product Officer
A Whole Foods grocery store is “in development” in St. Petersburg, according to a company spokesperson. Stop us if you’ve heard that one before. Rumors that the upscale and organic chain was eyeing locations in St. Petersburg go back at least as far as 2008, with one downtown site attracting lots of attention in 2012. Now, though, there actually appears to be some movement. St. Petersburg ...
The Society for Information Display (SID) is pleased to announce that registration http://www.displayweek.org/2021/Attendee/Registration.aspx is open for Display Week 2021. The all-virtual event will be held May 17-21. Display Week 2021 will bring together the brightest minds in the display industry to provide insight into the latest advancements and showcase new technologies and products that will be hitting the shelves both in the US and internationally within the next few years.
Shares of Ideanomics (NASDAQ: IDEX) have popped today, up by 17% as of 11:50 a.m. EST, after the company filed for a $150 million stock offering. Ideanomics is tapping Roth Capital Partners as its agent to sell stock. The shares are being offered pursuant to a shelf registration that Ideanomics had previously filed.
After Georgia's attorney general refused to reassign two high-profile cases involving allegations of excessive force against Atlanta police officers, including the killing of Rayshard Brooks, the district attorney is asking the court to decide who should handle the prosecutions. Newly elected Fulton County District Attorney Fani Willis sent a letter to Attorney General Chris Carr in January asking him to reassign the cases, raising concerns that actions by her predecessor, Paul Howard, made it inappropriate for her office continuing to handle the cases.
"While hotels have protocols in place to ensure limited contact between employees and guests, prioritizing employees with access to the vaccine would provide another layer of protection."
Creative director Pierpaolo Piccioli intrigued with a black and white coed and highly crafted fall 2021 collection.
Their financials are in good condition
Last September, in the arid hills of northern Nevada, a cluster of flowers found nowhere else on earth died mysteriously overnight. Conservationists were quick to suspect ioneer Ltd, an Australian firm that wants to mine the lithium that lies beneath the flowers for use in electric vehicle (EV) batteries. One conservation group alleged in a lawsuit that the flowers, known as Tiehm's buckwheat, were "dug up and destroyed."
Watch a preview for Harry and Meghan's tell-all interview.
Spoiler: It was glorious.
The Pfizer and AstraZeneca vaccines are more than 80% effective at preventing hospitalisations from COVID-19 in those over 80 after one dose of either shot, Public Health England (PHE) said on Monday, citing a pre-print study. PHE said the real world study, with data generated from Britain's vaccine rollout, also found that protection against symptomatic COVID in those over 70 ranged between 57-61% for one dose of Pfizer-BioNTech's vaccine and between 60-73% for the Oxford-AstraZeneca one four weeks after the first shot. "These results may also help to explain why the number of COVID admissions to intensive care units among people over 80 in the UK have dropped to single figures in the last couple of weeks, which is something I know that we all welcome," health minister Matt Hancock said at a news conference.
According to analyst Ming-Chi Kuo, the 2021 iPhone won't feature a drastically different design than its predecessor but could come with a smaller notch.
(Bloomberg) -- Big bank stocks regained their footing on Monday, with a fresh crop of analysts expressing bullish views on the industry’s prospects amid rebounding economic growth.The KBW Bank Index rose as much as 3.2% after shedding more than 5% in a two-day selloff as optimism about widespread vaccination, more government spending and a strengthening economy had turned into fear that rising bond yields and inflation would take a toll on companies and consumers.That concern eased on Monday as yields stabilized, allowing investors to turn their attention once again to the benefits of more stimulus and the potential end of lockdowns. Morgan Stanley raised big bank price targets and lifted estimates, with analyst Betsy Graseck noting that the economy appeared poised to break out due to Covid-19 vaccine distribution and new stimulus.She cited expectations for 10-year Treasury yields at 1.70% by year end, the resumption of buybacks and better credit, while flagging State Street Corp., Synchrony Financial, and Citigroup Inc. as top picks. State Street rose as much as 4.8% in Monday trading, heading toward its biggest advance since Jan. 6. Synchrony added 3.8% and Citigroup climbed as much as 5%. Jefferies strategists also highlighted potential share repurchases in recommending banks and energy stocks.Plus, bank stocks are the cheapest group in the S&P 500, while they’re set for rising earnings, according to Wells Fargo analyst Mike Mayo.“What’s not to like?” Mayo said in a phone interview, reiterating the three recent turning points he’s seen for banks: The efficacy of Pfizer’s Covid-19 vaccine in November; the Federal Reserve allowing for more buybacks in December, and January’s Georgia Senate elections, which paved the way for more government stimulus.Banks’ price-to-book ratios were at an all-time low until the Pfizer vaccine results, he noted, and are still in the bottom quartile among S&P 500 companies, he said.“Valuation for the big six banks has returned to pre-pandemic levels in terms of price-tangible book value,” Bloomberg Intelligence analyst Alison Williams said. She cited robust capital markets as helping the banks’ near-term return-on-equity prospects, while rising interest rates and better loan demand may be key in the second half of this year.JPMorgan Chase & Co. added as much as 2.2% on Monday, while Bank of America Corp. gained as much as 3.1% and Goldman Sachs Group Inc. climbed as much as 3.2%.Last week, Credit Suisse‘s Susan Roth Katzke wrote about the optimism of bank executives who spoke at the firm’s financial services conference, while noting flagged tepid lending as the post-pandemic recovery had yet to unfold.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
A healthcare worker holds a dose of the Johnson & Johnson vaccine against the COVID-19 coronavirus as South Africa proceeds with its inoculation campaign at the Klerksdorp Hospital on February 18, 2021. (Photo by Phill Magakoe / AFP) (Photo by PHILL MAGAKOE/AFP via Getty Images) Over the weekend, The U.S. Food and Drug Administration authorized Johnson & Johnson’s one-shot COVID-19 vaccine for emergency use. It’s now the third vaccine to be distributed across the nation, behind Moderna and Pfizer and their two-shot mRNA vaccines. Nearly 4 million doses of the newly approved vaccine were shipped out across the country on Sunday night, the first dose of which is set to be administered Tuesday. Deploying another vaccine will mean much to so many: to people itching to get a shot so they can see their grandkids; to the families of the more than 500,000 Americans who’ve died of COVID-19; but also, to the researchers and scientists who’ve worked tirelessly over the past year to help create a solution to our global crisis. Hanneke Schuitemaker, PhD, the vice president and global head of viral vaccine discovery and translational medicine at Johnson & Johnson, is one of those researchers. She helped develop the vaccine and has since been involved with analyzing the data from the Johnson & Johnson trials. I spoke with her back in April, when she was working 14-hour days to create a vaccine she deeply hoped would work. When her team released first released their phase three trial data showing their study determined the vaccine was safe and effective in January, I reached out to catch up. From her home office in The Netherlands, Dr. Schuitemaker spoke with me via Zoom in anticipation of the milestone achieved over this past weekend, telling me that her team is happy with their results, and have even carved out time in their schedules to celebrate some of their big wins virtually. But they’re also not done fighting. They’re looking for ways to improve their vaccine, and planning for how they’ll handle the new coronavirus variants sprouting up across the globe. During our call, she leaned in close to her camera, clasped her hands together, like she was about to let me in on a big secret, and said: “There’s always more work to be done.” Last time we talked in April, you were still in early stages of vaccine development, and had just picked a vaccine candidate to run with but had only tested it on animals at that point. Now, you’re so close to getting emergency approval for your vaccines. How do you feel? “Indeed, a lot has happened. When we first looked at the data from our phase three clinical trial, it said it was 66% effective overall and 72% effective in the U.S. in preventing symptomatic COVID. This was after we already knew Pfizer and Moderna’s efficacy numbers. At first, we thought — oh, no, this is not 90%. But we then realized, there’s no direct comparison. And our aim was always to have a vaccine that was 70% efficacious after one shot, because we know that is what will make a difference in this pandemic. It will prevent disease significantly. “When we looked into the data more deeply, we realized that across countries and virus lineages, or variants, we have very high protection against severe COVID-19. About 85%. Full protection against hospitalization. And we had no deaths in the vaccine group, when there were deaths in the group that received the placebo shot in our trial. That is quite an amazing result after one dose.” What’s been your biggest challenge and your biggest win? “Keeping everybody focused and energized has been tough, because the work conditions are so challenging. We cannot celebrate our highs because we’re just all by ourselves in our home offices, like everyone. The team is dedicated, but to work day and night and be in the dark about what the results will be for so long? Sometimes it was tough. You get to the end of your rope. You’re tired. You want sleep, and then in your sleep, you’re still dreaming about the vaccine. “But now, we’re pushing toward FDA emergency approval. What am I complaining about, really? We have a vaccine!” Did you do anything specific to keep morale up among your team? And how did you practice self-care yourself? “My team had a daily meeting where we motivated each other. We talked about the progress we were making. And it helped me personally to go walk my labrador, Figo. When I was worried, I’d think, Well, the sun will come up tomorrow, right? Time will help us. Keep breathing.” Last time we spoke, you were working 14-hour days. Is that still the case? “Sometimes it’s higher. But of course, I need to eat, sleep, and walk my dog. The time that I work keeps increasing in the evening. My dog is so fed up with it. He has started to bark. He is 11 years old and has never barked, but now realizes he needs to make sound to get some attention. Now I do my evenings with my laptop and him lying at my feet. He deserves attention, and it makes me realize that when this is over, I’ll need to log off and spend some time doing nothing and playing with him. “Right now, in the Netherlands, we have a lockdown and a curfew, so there’s not much to distract us. So we could just keep pushing and doing our work. It’s not a healthy life. I couldn’t do this forever. But I realize what a privilege it is to be part of this. I need to do all that I can to bring this global pandemic to an end. That weighs much heavier on me than the hours I need to put in. If a vaccine can be rolled out and it helps us get out of this crisis, it’s worth every minute.” That must be a lot of pressure, right? “Yes, it was tremendous pressure, especially once the virus variants came into play. We had to get immune response data for all regions in case we saw lower immune responses in areas where there were new variants. Everyone kept asking me where the data was. What can you tell us? When will you know? I was like, I can’t rush this. We need to let people do their work. I was ready to say that my internet broke so I couldn’t take the calls anymore. But that would have been childish. Now I feel more relaxed again, but there’s still a lot of work ahead of us. The trial is still ongoing. We’re working towards the FDA emergency use authorization. There are new challenges.” You’ve been quoted saying: “Treatments save lives, but vaccines save populations.” Can you tell me more about that philosophy and how it’s kept you going? “What you see in this crisis is that we can treat people, but we see around the world that the health care system is overwhelmed. So even if you have treatment, there are capacity limits for who can receive it. If we can prevent overwhelm with vaccines, we can save the population from the consequences and suffering of this pandemic. And that’s why we’re working tirelessly. We need herd immunity to save the population.” What do you think about the vaccine rollout so far? “I don’t know about for your country, but here it’s going pretty slow. It’s been heartbreaking to see these very old people who’ve felt unsafe for almost a year now. But when they get the vaccine, it gives them back their hopes. They can see their families and meet their grandchildren again. “But I think we could do a better job. I think we need to produce faster and more. Across the world I think we should do everything to get these vaccines to everybody.” Will the J&J vaccine help with that? “Yes. With our vaccine, one shot is enough. It’s great for people in remote areas, because they won’t have to come back after three, four weeks. It can be transported at more favorable temperatures than some of the others. Not saying it shouldn’t be rolled out in the Western world, but I think it has potential to be rolled out in more challenging areas of the world especially, to bring the vaccine to everybody.” Have you had your vaccine? “No! It’s funny, people say it’s not fair because I’ve worked on it all year. But I think it is fair. Because everybody is dealing with this crisis. Everybody wants to be vaccinated. I think it makes complete sense that the people who need it the most get vaccinated first. My only risk factor is my 20-year-old son, and I tell him every day to be careful. I’m not at high risk for contracting the virus, so those who are should be vaccinated first.” Once the process of getting this vaccine authorized is finished, what will you do next? I know you’ve worked in the past on other therapeutic vaccine candidates, like HIV, Ebola, and HPV. Will you go back to that work or focus on new generations of COVID-19 vaccines? “I’ll do both. I’m so proud of teams that have kept our other vaccine programs going. Our Ebola program is doing well. But we’re also working on next generation COVID-19 vaccines. We need to figure out: Do we need to do an update for the lineages circulating now? As a virologist, I believe there’s an end to what a virus can do mutation-wise. It still needs to bind to its host. The less the virus spreads, it will stop the emergence of new lineages which will get us out of this crisis. At a certain point, a virus needs to accept that it will be neutralized by antibodies and can’t escape any more. But we’re figuring out what our next steps will be.” Last time we talked, you said when this was all over, you were going to the Alps to hike. Do you think that will happen for you this year? Do you have hope that life will be normal enough for us all to do things like that in the next year? “Yes, I have two friends, and we said on New Year’s Eve of this year that we’re definitely going to go camping there this year. We’ll do it unless we cannot, due to COVID restrictions. But it’s my hope that we’ll have more immunity so that everybody can move around a little bit more. I’m so ready to hike and think of nothing for at least a week.” This interview has been condensed for length and clarity. Like what you see? How about some more R29 goodness, right here?Johnson & Johnson's One-Dose Vaccine FDA ApprovedHow Johnson & Johnson's Single-Shot Vaccine WorksWhy Are COVID Vaccines Only In Wealthy Communities
Chicago speed cameras will now issue tickets for people going just 6 miles per hour over the speed limit in certain areas.